曼吉费林是一种新的潜在抗疟疾和抗癌药物,用于向氨酸氧甲基转移酶
Somchart Maenpuen1, Pitchayathida Mee-Udorn2, Chatchadaporn Pinthong3
1Department of Biochemistry, Faculty of Science, Burapha University, Chonburi, 20131, Thailand.
Archives of biochemistry and biophysics
|August 5, 2023
概括
叶中的曼吉费林抑制了血清基甲基转移酶 (SHMT),这是抗疟疾和抗癌药物的标. 这项研究揭示了其作为对四基酸盐 (THF) 的竞争性抑制剂的机制.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- 曼吉费林是一种天然的克桑糖化物,具有多样化的生物活性.
- 血清基甲基转移酶 (SHMT) 对于核酸合成至关重要,也是抗疟疾和抗癌疗法的标.
- 曼吉费林对SHMT的抑制作用以前没有被研究过.
研究的目的:
- 为了研究曼吉费林抑制Plasmodium falciparum和人类细胞质SHMT.
- 使用体外和体内方法阐明曼吉费林抑制SHMT的机制.
- 探索曼吉费林作为治疗疟疾和癌症的治疗剂的潜力.
主要方法:
- 在体外酶抑制测定.
- 在基分子对接和分子动力学 (MD) 模拟中.
- 曼吉费林的质子解离平衡的表征 (pKa值).
主要成果:
- 曼吉费林在pH7.5下竞争性地抑制了P. falciparum和人细胞质SHMT与四基酸盐 (THF) 相比.
- 分子模拟确定了在THF口袋内结合的去质子化曼吉费林物种 (C6-O-和C9-O-).
- 曼吉费林的基团 (C6-OH,C3-OH,C7-OH) 在生理pH时表现出不同的脱质.
结论:
- 曼吉费林表现出一种针对SHMT的新型抑制活性.
- 对THF的竞争性抑制机制得到了结构和动态模拟的支持.
- 这些发现支持曼吉费林作为一种潜在的抗疟疾和抗癌药物的发展.
更多相关视频
09:03Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
Published on: January 26, 2024
403
06:07Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
2.6K
相关概念视频
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Electron Transport Chain: Complex I and II
14.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.5K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
